Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2017)
Spero Therapeutics (SPRO) reported Income from Non-Controlling Interests of -$6000.0 for Q4 2017, up 99.39% on a YoY basis from -$3009.2 in Q4 2016, and up 25.0% quarter-over-quarter from -$8000.0 in Q3 2017.
Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2017) Analysis & Trends
Spero Therapeutics has reported Income from Non-Controlling Interests for 2 years, with the latest figure at -$6000.0 in Q4 2017.
- For the quarter ending Q4 2017, Income from Non-Controlling Interests rose 99.39% year-over-year to -$6000.0; the trailing twelve-month figure through Dec 2017 stood at -$1.1 million (changed N/A YoY), and the FY2017 full-year result was -$1.1 million, up 84.01% from the prior year.
- Income from Non-Controlling Interests for Q4 2017 stood at -$6000.0, up from -$8000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$6000.0 in Q4 2017, with the low at -$1.6 million in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Spero Therapeutics | 129.74 Mn | 73.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -6,000.00 |
| Sep 30, 2017 | -8,000.00 |
| Jun 30, 2017 | -594,000.00 |
| Mar 31, 2017 | -535,000.00 |
| Dec 31, 2016 | -986,000.00 |
| Sep 30, 2016 | -1.60 Mn |